$0.100
-0.025 (-24.98%)Al cierre
- High
- 0.131
- Open
- 0.126
- VWAP
- 0.10
- Vol
- 4.48M
- Mkt Cap
- 21.86M
- Low
- 0.081
- Amount
- 465.44K
- EV/EBITDA, TTM
- 0.00
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers.
Métricas de valoración
Cronología de eventos
Noticias
7.512-22GlobenewswireVince Trust Launches Christmas Rewards Program Offering Up to $10,000 in Incentives
7.512-19GlobenewswireVince Trust Launches Christmas User Incentive Program Offering Up to $6,400 in Rewards
4.504-21BenzingaUS Stocks Likely To Open Lower: 'Best And Worst Days Tend To Occur Near The Same Time,' Says Expert
9.004-17NewsfilterVincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC
9.004-17Business InsiderVincerx Pharma announces plan to delist from Nasdaq
VINC FAQ — answered by Alphio AI
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company that is focused on the development and oncology knowledge to advance new therapies to address unmet medical needs for the treatment of cancer. The Company’s pipeline consists of enitociclib, which is in Phase I, and a modular bioconjugation platform, which includes a small molecule drug-conjugate (SMDC), VIP236, in Phase I, and preclinical next-generation antibody drug-conjugates, VIP943 and VIP924. Enitociclib, is a highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. The Company's antibody-drug conjugate (ADC) platform includes VIP943 and VIP924, which are ADC compounds addressing known and oncology targets. The bioconjugation program also includes VIP236, which is a small molecule drug conjugate (SMDC) for solid tumors. VIP236 is a SMDC with a focus on treating patients with cancers. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.